全文获取类型
收费全文 | 44篇 |
免费 | 14篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 14篇 |
内科学 | 26篇 |
皮肤病学 | 2篇 |
神经病学 | 2篇 |
外科学 | 7篇 |
综合类 | 1篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 1篇 |
肿瘤学 | 1篇 |
出版年
2017年 | 3篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 5篇 |
2013年 | 8篇 |
2011年 | 1篇 |
2010年 | 5篇 |
2009年 | 7篇 |
2008年 | 1篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2005年 | 1篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1992年 | 1篇 |
1990年 | 1篇 |
1974年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有58条查询结果,搜索用时 15 毫秒
31.
K. NINAN CHACKO JENNY L. DONOVAN PAUL ABRAMS TIM J. PETERS SARA T. BROOKES ANDY C. THORPE SANDEEP GUJRAL MARK WRIGHT L. GAIL KENNEDY DAVID E. NEAL 《The Journal of urology》2001,166(1):166-70; discussion 170-1
PURPOSE: Transurethral resection of the prostate is the standard operation for acute urinary retention, although laser prostatectomy is reportedly effective and safe. The ClasP (conservative management, laser, transurethral resection of the prostate) study compared transurethral prostatic resection and noncontact neodymium (Nd):YAG visual laser assisted prostatectomy for treatment of acute urinary retention. MATERIALS AND METHODS: This study was a multicenter randomized controlled trial, analyses were by intention to treat and followup was at 7.5 months after randomization. Primary outcomes were treatment failure, and included International Prostate Symptom Score, International Prostate Symptom Score quality of life score, residual urine and flow rate. Secondary outcomes included complications, and duration of catheterization and hospitalization. RESULTS: A total of 148 men were randomized to transurethral prostatic resection (74) and laser (74). There were fewer treatment failures after prostatic resection (p = 0.008) and fewer men after resection required secondary surgery for poor results (1 versus 7, p = 0.029). Maximum flow rates after transurethral prostatic resection were better than after laser (mean difference 4.4 ml. per second). Comparison of symptom and quality of life scores demonstrated that any clinically significant advantage for laser could be ruled out. Patients stayed a mean of 2 extra days in the hospital after resection. The duration of catheterization was greater after laser but significantly fewer major treatment complications were found with laser therapy. CONCLUSIONS: Transurethral prostatic resection was more effective, resulted in fewer failures than laser treatment and remains the procedure of choice for men with acute urinary retention. 相似文献
32.
33.
34.
KABIR SARDANA M.D. DNB MNAMS SHIKHA BANSAL M.D. DNB † VIJAY K. GARG M.D. MNAMS NITA KHURANA M.D. † 《Pediatric dermatology》2009,26(5):626-628
Abstract: A 17-year-old boy presented with papules and nodules arranged linearly on the neck and on the forehead. A diagnosis of collagenoma was made. Intralesional injection of triamcinolone acetonide resulted in marked effacement of the lesions. 相似文献
35.
SANDEEP BASAVARAJAIAH M.R.C.P. M.D. AZEEM LATIB M.D. TASUKU HASEGAWA M.D. AHMED REZQ M.D. KENSUKE TAKAGI M.D. TORU NAGANUMA M.D. MASA KAWAGUCHI M.D. FILIPPO FIGINI M.D. ANTONIO COLOMBO M.D. 《Journal of interventional cardiology》2013,26(3):259-263
Objectives
To assess the safety and efficacy of combining drug‐eluting balloon (DEB) and drug‐eluting stents (DES) in the same coronary lesion.Background
Use of DEB may not always produce optimal results or even result in dissection, compelling the operators to consider bailout stenting with bare metal stents (BMS). However, BMS may not be ideal in patients who have significant risk‐profile for restenosis. We have opted for DES over BMS in such situations and present our follow‐up data.Methods
Between 2009 and 2011, 46 patients (57 lesions) requiring bailout stenting following DEB use were treated with second‐generation DES. All patients had at‐least one or more risk‐factors that made them vulnerable for restenosis (diabetes, chronic kidney disease, previous in‐stent restenosis [ISR], and/or long diffuse lesions ≥30 mm).Results
Of the 57 lesions, 34 (60%) were previous ISR. The mean length of the DEB was: 36.2 ± 5.6 mm. All patients had TIMI‐3 flow post PCI with no in‐lab complications. At median follow‐up of 12.3 months (interquartile range [IQR]: 7.5–18.1), the rates target lesion revascularization (TLR) and target vessel revascularization (TVR) were 3 (5.3%) and 4 (7%), respectively. One patient had died 3 months following treatment. There were no episodes of myocardial infarction, definite or probable stent thrombosis. The major adverse cardiovascular events (MACE) rate defined as cardiac‐death, MI, and TVR occurred in 11% of patients.Conclusion
The results from this novel strategy of combining “Paclitaxel” eluting balloon and “Limus” eluting stent in a same lesion are encouraging. Dual drug‐elution acting on two different pathways may provide potential synergy that may explain the favorable outcome. (J Interven Cardiol 2013;26:259–263)36.
HUMERA AHMED B.A. MARC A. MILLER M.D. SRINIVAS R. DUKKIPATI M.D. SAM CAMMACK M.P.H. JACOB S. KORUTH M.D. SANDEEP GANGIREDDY M.D. BETSY A. ELLSWORTH M.S.N. ANDRE D'AVILA M.D. Ph.D. MICHAEL DOMANSKI M.D. ANNETINE C. GELIJNS Ph.D. ALAN MOSKOWITZ M.D. VIVEK Y. REDDY M.D. 《Journal of cardiovascular electrophysiology》2013,24(5):503-509
37.
38.
39.
Rapid Device‐Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy 下载免费PDF全文
40.
MICHAEL ABSOUD JEREMY R PARR DOROTHY HALLIDAY PIETER PRETORIUS ZENOBIA ZAIWALLA SANDEEP JAYAWANT 《Developmental medicine and child neurology》2010,52(3):305-307
ARX mutations are associated with variable clinical phenotypes. We report a new neurodegenerative phenotype associated with a known ARX mutation and causing early abnormal neurodevelopment, a complex movement disorder, and early infantile epileptic encephalopathy with a suppression‐burst pattern (Ohtahara syndrome). A male infant presented at age 5 months with a dyskinetic movement disorder, which was initially diagnosed as infantile spasms. Clinical deterioration was accompanied by progressive cortical atrophy with a reduction in white matter volume and resulting in death in the first year of life; such a rapidly progressive and severe phenotype has not previously been described. ARX mutation testing should be undertaken in children aged less than 1 year with Ohtahara syndrome and a movement disorder, and in infants with unexplained neurodegeneration, progressive white matter loss, and cortical atrophy. 相似文献